Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis

Aiman Abu Ammar*, Abed Nasereddin, Suheir Ereqat, Mary Dan-Goor, Charles L. Jaffe, Eyal Zussman, Ziad Abdeen

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

59 Scopus citations

Abstract

Cutaneous leishmaniasis (CL) is an infectious, parasitic disease caused by the protozoan Leishmania. Amphotericin B (AMB) is a macrolide polyene antibiotic presenting potent antifungal and antileishmanial activity, but due to poor water solubility at physiological pH, side effects, and toxicity, its therapeutic efficiency is limited. In the present study, poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) loaded with AMB were generated to reduce drug toxicity and facilitate localized delivery over a prolonged time. AMB NPs were characterized for particle size, zeta potential, polydispersity index, and degree of aggregation. In vitro assessments demonstrated its sustained activity against Leishmania major promastigotes and parasite-infected macrophages. A single intralesional administration to infected BALB/c mice revealed that AMB NPs were more effective than AMB deoxycholate in terms of reducing lesion area. Taken together, these findings suggest that AMB NPs improve AMB delivery and can be used for local treatment of CL.

Original languageEnglish
Pages (from-to)76-84
Number of pages9
JournalDrug Delivery and Translational Research
Volume9
Issue number1
DOIs
StatePublished - 15 Feb 2019
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2018, Controlled Release Society.

Keywords

  • Amphotericin B
  • Cutaneous leishmaniasis
  • Nanoparticles
  • Sustained release
  • Topical therapy

Fingerprint

Dive into the research topics of 'Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis'. Together they form a unique fingerprint.

Cite this